1859 Inc. is a platform company combining artificial intelligence and empirical screening data at scale to discover new small molecule medicines for emerging disease targets. The company partners with pharmaceutical and biotech companies, and academic institutions to dramatically shorten the time and resources needed to identify and screen high-potential compounds for future exploration and development.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/07/22 | $40,000,000 | Series A |
FusionX Ventures Northpond Ventures  OMX Ventures Vertical Venture Partners | undisclosed |
